Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320377 | 0.82 | HSD11B1 (0.34) | HSD11B1PSMB5RARBBRS3 | |
| SCHEMBL10319158 | 0.82 | HSD11B1 (0.35) | HSD11B1PSMB5GPR84RARBBRS3 | |
| SCHEMBL10320660 | 0.76 | HSD11B1 (0.34) | HSD11B1PSMB5GPR84RARBCTSV | |
| SCHEMBL10319420 | 0.75 | BRD4 (0.33) | — | |
| SCHEMBL10320396 | 0.74 | HSD11B1 (0.34) | HSD11B1GPR84RARBTOP2AMAPT | |
| SCHEMBL10320818 | 0.73 | HSD11B1 (0.35) | HSD11B1PSMB5GPR84RARBBRS3 | |
| SCHEMBL10318652 | 0.72 | HSD11B1 (0.32) | HSD11B1GPR84RARBBRS3 | |
| SCHEMBL10320511 | 0.72 | HSD11B1 (0.32) | HSD11B1GPR84RARBBRS3 | |
| SCHEMBL10317155 | 0.72 | HSD11B1 (0.34) | HSD11B1PSMB5GPR84RARBBRS3 | |
| SCHEMBL10318619 | 0.72 | GPR84 (0.35) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9919300-B2 | 1-hexene production process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-2484685-B1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20170036200-A1 | 1-HEXENE PRODUCTION PROCESS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20150105237-A1 | CATALYTIC COMPONENT FOR TRIMERIZATION AND TRIMERIZATION CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105572-A1 | TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2484685-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | Sumitomo Chemical Co., Ltd (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184431-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170036200-A1 | 1-HEXENE PRODUCTION PROCESS | AP1M1, HK1, CYC1 | HSD11B1 415/4885PSMB5 1306/4885GPR84 3260/4885 |
| US-20150105572-A1 | TRANSITION METAL COMPLEX | AP1M1, AP3M1, EMC1 | HSD11B1 751/4885PSMB5 1451/4885GPR84 3787/4885 |
| US-20150105237-A1 | CATALYTIC COMPONENT FOR TRIMERIZATION AND TRIMERIZATION CATALYST | AP1M1, AMY1A, AP3M1 | HSD11B1 477/4885PSMB5 1693/4885GPR84 2592/4885 |
| US-20120184431-A1 | TRANSITION METAL COMPLEX, PREPARATION METHOD FOR SAID TRANSITION METAL COMPLEX, TRIMERIZATION CATALYST, PREPARATION METHOD FOR 1-HEXENE, PREPARATION METHOD FOR ETHYLENE POLYMER, SUBSTITUTED CYCLOPENTADIENE COMPOUND, AND PREPARATION METHOD FOR SAID SUBSTITUTED CYCLOPENTADIENE COMPOUND | EMC1, CYC1, AP1M1 | HSD11B1 377/4885PSMB5 1398/4885GPR84 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.